Ethosuximide

Ethosuximide is a succinimide anticonvulsant, used mainly in absence seizures. It is sold by Pfizer under the name Zarontin® and was once also sold under the name Emeside®, both of which were discontinued from the United Kingdom market in capsule form in November of 2005.^[2]

Additional recommended knowledge

Weighing the right way

Essential Laboratory Skills Guide

Guide to balance cleaning: 8 simple steps

Uses

Approved

It is approved for absence seizures.^[3] Ethosuximide is considered the first choice drug for treating absence seizures in part because it lacks the idiosyncratic hepatotoxicity of the alternative anti-absence drug, valproic acid.^[4]

Unapproved

It was reported to have been used for intermittent explosive disorder in 1980 by Drs Andrulonis, Donnelly, Glueck, Stroebel, and Szabek.^[5]

Dosage

Therapeutic drug concentrations are individualized according to response and tolerance. Common Serum Therapeutic Range: 40-100 µg/mL. Potentially Toxic Serum Concentration: >100 µg/mL.

Mechanism of action

There is some controversy over the exact mechanism by which ethosuximide prevents absence seizures. While the view that ethosuximide is a T-type calcium channel blocker gained widespread support following its proposal, attempts to replicate the initial finding were inconsistent.

In March of 1989, Coulter, Huguenard and Prince showed that ethosuximide and dimethadione, both effective anti-absence agents, reduced low-threshold Ca²⁺ currents in T-type Ca²⁺ channels in freshly removed thalamic neurons.^[6] In June of that same year, they also found the mechanism of this reduction to be voltage-dependent, using acutely neurons of rats and guinea pigs; it was also noted that valproic acid, which is also used in absence seizures, did not do that.^[7] The next year, they showed that anticonvulsant succinimides did this and that the proconvulsant ones did not.^[8] The first part was supported by Kostyuk et al in 1992, who reported a substantial reduction in current in dorsal root ganglia at concentrations ranging from 7 µmol/L to 1 mmol/L.^[9]

That same year, however, Herrington and Lingle found no such effect at concentrations of up to 2.5 mmol/L.^[10] The year after, a study conducted on human neocortical cells removed during surgery for intractable epilepsy, the first to use human tissue, found that ethosuximide had no effect on Ca²⁺ currents at the concentrations typically needed for a therapeutic effect.^[11]

In 1998, Slobodan M. Todorovic and Christopher J. Lingle of Washington University reported a 100% block of T-type current in dorsal root ganglia at 23.7 ± 0.5 mmol/L, far higher than Kostyuk reported.^[12] That same year, Leresche et al reported that ethosuximide had no effect on T-type currents, but did decrease noninactivating Na⁺ current by 60% and the Ca²⁺-activated K⁺ currents by 39.1 ± 6.4% in rat and cat thalamocortical cells. It was concluded that the decrease in Na⁺ current is responsible for the anti-absence properties.^[13]

In the introduction of a paper published in 2001, Dr. Juan Carlos Gomora and colleagues at the University of Virginia in Charlottesville pointed out that past studies were often done in isolated neurons that had lost most of their T-type channels.^[14] Using cloned α1G, α1H, and α1I T-type calcium channels, Gomora's team found that ethosuximide blocked the channels with an IC₅₀ of 12 ± 2 mmol/L and that of N-desmethylmethsuximide (the active metabolite of mesuximide) is 1.95 ± 0.19 mmol/L for α1G, 1.82 ± 0.16 mmol/L for α1I, and 3.0 ± 0.3 mmol/L for α1H. It was suggested that the blockade of open channels is facilitated by ethosuximide's physically plugging the channels when current flows inward.

Adverse effects

Central nervous system

Common

• drowsiness
• mental confusion
• insomnia
• nervousness
• headache
• euphoria
• ataxia
• hiccups
• impaired concentration
• irritability
• hyperactivity
• loss of taste
• night terrors

Rare

• paranoid psychosis
• increased libido
• exacerbation of depression

Gastrointestinal

• dyspepsia
• vomiting
• nausea
• cramps
• constipation
• diarrhea
• stomach pain
• loss of appetite
• weight loss
• gingival hyperplasia
• swelling of tongue

Genitourinary

• microscopic hematuria
• vaginal bleeding

Hematopoietic

The following can occur with or without bone marrow loss:

• pancytopenia
• agranulocytosis
• leukopenia
• eosinophilia

Integumentary

• urticaria
• systemic lupus erythematosus
• Stevens-Johnson syndrome
• hirsutism
• pruritic erythematous rashes

Ocular

• myopia

Complications

• abnormal liver function

Drug interactions

Valproates can either decrease or increase the levels of ethosuximide; However, combinations of valproates and ethosuximide had a greater Protective Index than either drug alone.^[15]

It may elevate serum phenytoin levels.

References

Sources

• Ethosuximide Internet Mental Health.
• MedlinePlus Drug Information: Ethosuximide Oral
• Zarontin® Pfizer.
• Zarontin® Drug information, published studies and current trials

Notes

1. ^  Patsalos, P. N. (November 2005). "Properties of Antiepileptic Drugs in the Treatment of Idiopathic Generalized Epilepsies". Epilepsia 46 (s9): 140-144. PMID 16302888.
2. ^  Epilepsy Research Foundation (2005). Withdrawal of Zarontin and Emeside tablets. Retrieved on 2007-05-14.
3. ^  Pharmaceutical Associates, Incorporated (2000). Ethosuximide Approval Label (PDF). Label and Approval History. Food and Drug Administration Center for Drug Evaluation and Research. Retrieved on 2006-02-05.
4. ^  "Drugs used in generalized seizures." Katzung, B. Basic and Clinical Pharmacology. 9th Ed. 2003. Lange Medical Books/McGraw-Hill.0071410929.
5. ^  Andrulonis, P. A.; J. Donnelly, B. C. Glueck, C. F. Stroebel, and B. L. Szabek (November 1980). "Preliminary data on ethosuximide and the episodic dyscontrol syndrome". American Journal of Psychiatry 137 (11): 1455-6. PubMed.
6. ^  Coulter DA, Huguenard JR, Prince DA. "Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons." Neurosci Lett. 1989 Mar 13;98(1):74-8. PMID 2710401
7. ^  "Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons." Annals of Neurology. 1989 Jun;25(6):582-93. PMID 2545161
8. ^  Coulter DA, Huguenard JR, Prince DA. "Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction." British Journal of Pharmacology. 1990 Aug;100(4):800-6. PMID 2169941
9. ^  Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN. "Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons." Neuroscience. 1992 Dec;51(4):755-8. PMID 1336826
10. ^  Herrington J, Lingle CJ (1992 Jul). "Kinetic and pharmacological properties of low voltage-activated Ca2+ current in rat clonal (GH3) pituitary cells". Journal of Neurophysiology 68 (1): 213-32. PMID 1325546.
11. ^  Sayer RJ, Brown AM, Schwindt PC, Crill WE. "Calcium currents in acutely isolated human neocortical neurons." Journal of Neurophysiology. 1993 May;69(5):1596-606. PMID 8389832 Fulltext
12. ^  Todorovic SM, Lingle CJ (1998). "Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents". Journal of Neurophysiology 79 (1): 240-52. PMID 9425195.
13. ^  Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, Asprodini E, Crunelli V (1998). "On the action of the anti-absence drug ethosuximide in the rat and cat thalamus". Journal of Neuroscience 18 (13): 4842-53. PMID 9634550.
14. ^  Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E (2001). "Block of cloned human T-type calcium channels by succinimide antiepileptic drugs". Molecular Pharmacology 60 (5): 1121-32. PMID 11641441.
15. ^  Bourgeois, BF (1988 Dec). "Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction". The Journal of Pharmacology and Experimental Therapeutics 247 (3): 1128-32. PMID 3144596.

Carbamates: Emylcamate, Felbamate, Meprobamate -- Pyrrolidines: Brivaracetam, Levetiracetam, Nefiracetam, Seletracetam